These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20704560)

  • 1. Why so few drugs for Alzheimer's disease? Are methods failing drugs?
    Becker RE; Greig NH
    Curr Alzheimer Res; 2010 Nov; 7(7):642-51. PubMed ID: 20704560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
    Becker RE; Greig NH
    Alzheimers Dement; 2013 Jan; 9(1):50-7. PubMed ID: 22465172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The perils of Alzheimer's drug development.
    Schneider LS; Lahiri DK
    Curr Alzheimer Res; 2009 Feb; 6(1):77-8. PubMed ID: 19199878
    [No Abstract]   [Full Text] [Related]  

  • 4. Was phenserine a failure or were investigators mislead by methods?
    Becker RE; Greig NH
    Curr Alzheimer Res; 2012 Dec; 9(10):1174-81. PubMed ID: 23227991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the success rate for Alzheimer's disease drug discovery and development.
    Becker RE; Greig NH
    Expert Opin Drug Discov; 2012 Apr; 7(4):367-70. PubMed ID: 22439785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.
    Becker RE; Greig NH
    Curr Alzheimer Res; 2008 Aug; 5(4):346-57. PubMed ID: 18690832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease drug development: old problems require new priorities.
    Becker RE; Greig NH
    CNS Neurol Disord Drug Targets; 2008 Dec; 7(6):499-511. PubMed ID: 19128207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease?
    Doig AJ; Del Castillo-Frias MP; Berthoumieu O; Tarus B; Nasica-Labouze J; Sterpone F; Nguyen PH; Hooper NM; Faller P; Derreumaux P
    ACS Chem Neurosci; 2017 Jul; 8(7):1435-1437. PubMed ID: 28586203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.
    Lilja AM; Luo Y; Yu QS; Röjdner J; Li Y; Marini AM; Marutle A; Nordberg A; Greig NH
    PLoS One; 2013; 8(1):e54887. PubMed ID: 23382994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Drugs from Marine Organisms in Alzheimer's Disease.
    Russo P; Kisialiou A; Lamonaca P; Moroni R; Prinzi G; Fini M
    Mar Drugs; 2015 Dec; 14(1):5. PubMed ID: 26712769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
    Salomone S; Caraci F; Leggio GM; Fedotova J; Drago F
    Br J Clin Pharmacol; 2012 Apr; 73(4):504-17. PubMed ID: 22035455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study methods of drugs in Alzheimer disease].
    Dubois B; Stehlé B; Lehner JP; Derouesné C; Bourin M; Lamour Y; Blin O; Jourdain G; Alperovitch A
    Therapie; 1996; 51(4):444-8. PubMed ID: 8953828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
    Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Alzheimer's disease drug development.
    Rafii MS; Aisen PS
    BMC Med; 2015 Mar; 13():62. PubMed ID: 25857341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodologies Related to Computational Models in View of Developing Anti-Alzheimer Drugs: An Overview.
    Baheti K; Kale M
    Curr Drug Discov Technol; 2019; 16(1):66-73. PubMed ID: 29663890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
    Becker RE; Greig NH; Giacobini E
    J Alzheimers Dis; 2008 Oct; 15(2):303-25. PubMed ID: 18953116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.